Urinary kidney injury molecule 1(uKIM-1)serves as a reliable marker for the early diagnosis of acute kidney injury(AKI).The rapid and facile detection of changes in uKIM-1 is essential for early AKI diagnosis,ultimate...Urinary kidney injury molecule 1(uKIM-1)serves as a reliable marker for the early diagnosis of acute kidney injury(AKI).The rapid and facile detection of changes in uKIM-1 is essential for early AKI diagnosis,ultimately improving the prognosis of patients.In this study,we developed a fully printed photonic crystal-integrated microarray with photonic crystal-enhanced fluorescence properties,which can detect uKIM-1 levels at the point-of-care.We confirmed its efficacy in the early diagnosis of AKI using clinical urine specimens.Direct quantitative detection of uKIM-1 was achieved within 10 min.The lowest limit of detection is 8.75 pg·mL^(-1) with an accuracy of 94.2%.The diagnostic efficacy was validated using 86 clinical urine samples,highlighting the high sensitivity and stability of the photonic crystal microarray.Consequently,a facile and reliable immunoassay was designed and prepared for the rapid quantitative detection of uKIM-1,which is crucial for the early identification and convenient detection of AKI in hospital or community settings.Rapid,convenient,cost-effective,and long-term monitoring of changes in uKIM-1 levels can assist clinicians in making timely adjustments to treatment regimens,preventing the transition from AKI to chronic kidney disease(CKD),improving the quality of life of patients with AKI,and reducing healthcare costs.It highlights the advantages of utilizing urine samples as a noninvasive and easily accessible medium for early detection and monitoring of kidney-related conditions.展开更多
Migraine exhibits a substantial prevalence worldwide.The current diagnostic criteria rests exclusively on clinical characteristics without any objective and reliable means.The calcitonin gene-related peptide(CGRP),as ...Migraine exhibits a substantial prevalence worldwide.The current diagnostic criteria rests exclusively on clinical characteristics without any objective and reliable means.The calcitonin gene-related peptide(CGRP),as a biomarker for distinguishing migraine,undergoes swift degradation,featuring a half-life of under 10min,which poses a significant challenge to the point-of-care testing of CGRP in clinical application.Here,a photonic crystal(PC)-based biochip has been developed to detect CGRP via the fluorescence competition assay.The chip integrates the functionalities of fluorescence enhancement and hydrophilic–hydrophobic patterning enrichment,enabling rapid and sensitive detection of CGRP.After investigating the optimal enhancement distance of fluorescence near PCs,the chip allows CGRP detection using<30μL of saliva at room temperature within 10 min.A minimum detection limit of 0.05 pg/mL is achieved.Furthermore,CGRP concentrations in the saliva of 70 subjects have been tested by PC biochips.The results exhibit strong concordance with the enzyme-linked immunosorbent assay(ELISA),demonstrating a linear correlation coefficient of R 2 of 0.97.This sensitive detection of markers within such a short duration surpasses the capacities of ELISA,which paves the way for establishing a precise diagnostic framework integrating clinical phenotypes and biomarkers for migraine.展开更多
基金supported by the National Natural Science Foundation of China(Nos.82170684,52222313,22075296,91963212,82000004)the Health Care Program Foundation of PLA(No.21BJZ17)+2 种基金the Youth Independent Innovation Science Fund of the General Hospital of the People’s Liberation Army(No.22QNFC007)the Youth Innovation Promotion Association CAS(No.2020032)the Intramural Research Fund of Peking University International Hospital(No.YN2021QN05).
文摘Urinary kidney injury molecule 1(uKIM-1)serves as a reliable marker for the early diagnosis of acute kidney injury(AKI).The rapid and facile detection of changes in uKIM-1 is essential for early AKI diagnosis,ultimately improving the prognosis of patients.In this study,we developed a fully printed photonic crystal-integrated microarray with photonic crystal-enhanced fluorescence properties,which can detect uKIM-1 levels at the point-of-care.We confirmed its efficacy in the early diagnosis of AKI using clinical urine specimens.Direct quantitative detection of uKIM-1 was achieved within 10 min.The lowest limit of detection is 8.75 pg·mL^(-1) with an accuracy of 94.2%.The diagnostic efficacy was validated using 86 clinical urine samples,highlighting the high sensitivity and stability of the photonic crystal microarray.Consequently,a facile and reliable immunoassay was designed and prepared for the rapid quantitative detection of uKIM-1,which is crucial for the early identification and convenient detection of AKI in hospital or community settings.Rapid,convenient,cost-effective,and long-term monitoring of changes in uKIM-1 levels can assist clinicians in making timely adjustments to treatment regimens,preventing the transition from AKI to chronic kidney disease(CKD),improving the quality of life of patients with AKI,and reducing healthcare costs.It highlights the advantages of utilizing urine samples as a noninvasive and easily accessible medium for early detection and monitoring of kidney-related conditions.
基金Youth Innovation Promotion Association CAS,Grant/Award Number:2020032National Nature Science Foundation of China,Grant/Award Numbers:22075296,52222313,91963212+2 种基金Beijing National Laboratory for Molecular Sciences,Grant/Award Number:BNLMS-CXXM-202005Beijing Nova Program,Grant/Award Numbers:Z201100006820037,Z211100002121001National Nature Science Foundation of China,Grant/Award Number:82171208。
文摘Migraine exhibits a substantial prevalence worldwide.The current diagnostic criteria rests exclusively on clinical characteristics without any objective and reliable means.The calcitonin gene-related peptide(CGRP),as a biomarker for distinguishing migraine,undergoes swift degradation,featuring a half-life of under 10min,which poses a significant challenge to the point-of-care testing of CGRP in clinical application.Here,a photonic crystal(PC)-based biochip has been developed to detect CGRP via the fluorescence competition assay.The chip integrates the functionalities of fluorescence enhancement and hydrophilic–hydrophobic patterning enrichment,enabling rapid and sensitive detection of CGRP.After investigating the optimal enhancement distance of fluorescence near PCs,the chip allows CGRP detection using<30μL of saliva at room temperature within 10 min.A minimum detection limit of 0.05 pg/mL is achieved.Furthermore,CGRP concentrations in the saliva of 70 subjects have been tested by PC biochips.The results exhibit strong concordance with the enzyme-linked immunosorbent assay(ELISA),demonstrating a linear correlation coefficient of R 2 of 0.97.This sensitive detection of markers within such a short duration surpasses the capacities of ELISA,which paves the way for establishing a precise diagnostic framework integrating clinical phenotypes and biomarkers for migraine.
